The collaboration will leverage BIND’s Medicinal Nanoengineering technology for the addition of tissue and cellular targeting capabilities to molecularly targeted drugs.
BIND president and CEO Scott Minick said the agreement signifies the platform’s potential in creating Accurins with optimized therapeutic properties.
"This is our second collaboration focused on developing novel Accurins based on BIND’s platform for targeted and programmable therapeutics and further validates the importance of targeted nanomedicines as a strategic technology for the pharmaceutical industry," Minick added.
According to the deal, both the companies will work on preclinical research of Accurins.
Pfizer has an option to take up the development and commercialization activities of selected Accurins.
BIND is eligible for upfront and development milestone payments worth $50m, regulatory and sales milestone payments worth $160m in addition to potential sales-based tiered royalties.
Pfizer PharmaTherapeutics R&D senior vice president and head Rod MacKenzie said, "We look forward to working with the team at BIND Therapeutics to create targeted Accurins with the aim of optimizing the therapeutic potential of future small molecules."